Devices and technology: Continuous glucose monitoring

Results of a pilot study show that a hybrid closed-loop insulin delivery system customized for pregnancy used by women with type 1 diabetes at home significantly improved their glucose outcomes.

Data from the DPV cohort show a reduced risk for severe hypoglycemia and diabetic ketoacidosis among children and young people with type 1 diabetes using continuous glucose monitoring rather than self-monitored blood glucose.

The benefits of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes are sustained for at least 2 years, shows the extension of the ALERTT1 study.

Fully subsidizing continuous glucose monitors could overcome disparities in their use by people with diabetes, suggests research conducted in adults enrolled in a US Medicaid program.

Analysis of participants in the ORACL trial leads researchers to suggest that nonfrail older adults with type 1 diabetes are better off following time in range guidance aimed at younger people.

Brief, repeated use of real-time continuous glucose monitoring may help to improve glycemic control in people with type 2 diabetes who would otherwise need to escalate to insulin, suggests a small randomized trial.

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

Most parents of children starting continuous glucose monitoring soon after their type 1 diabetes diagnosis find virtual initiation to be convenient and effective, shows a small study.

Early findings from the Hypo-METRICS trial indicate that people with diabetes are unaware on most of the occasions that their blood glucose dips into the hypoglycemic range.

The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.

Follow-up results from the WISDM trial show that extended use of continuous glucose monitoring leads to reduced hypoglycemia without increasing hyperglycemia risk in older people with type 1 diabetes.

The Dexcom G7 continuous glucose monitor is accurate and well tolerated for up to 10.5 days when worn on the arm or abdomen, a study of adults with diabetes suggests.

Individuals with type 1 diabetes continue to experience severe and level 2 hypoglycemia despite the use of continuous glucose monitoring systems, with the risk potentially influenced by personal beliefs, US research shows.

Structured monitoring of blood glucose improves its control regardless of the device used, although continuous glucose monitoring is better than self-monitored blood glucose for reducing hypoglycemia, shows a randomized trial.

Hybrid closed-loop therapy significantly improves glycemic control and quality of life relative to continuous subcutaneous insulin infusion or multiple daily insulin injections in children and adolescents with type 1 diabetes, research shows.

Discontinuing continuous glucose monitoring leads to the loss of approximately half of the additional time in glycemic range accrued during its use among people with type 2 diabetes, MOBILE study data show.

Use of continuous glucose monitoring within the first month of diagnosis is associated with an improvement in glycemic control among youth with type 1 diabetes, indicate findings from the 4T study.

The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.

Switching from intermittently scanned to real-time continuous glucose monitoring improves time in range by a clinically relevant percentage, show the findings of the 6-month ALERTT1 trial.

People with impaired hypoglycemia awareness become more proactive about treating low blood glucose when they start using continuous glucose monitoring, but do not adjust their insulin usage, show data from HypoDE.